Subscribe to RSS

DOI: 10.1055/s-0045-1813008
Multidisciplinary Management of Children with Non-Wilms Renal Tumor: A Real-World Evidence from a Tertiary Cancer Care Center in Southern India
Authors
Funding None.
Abstract
Introduction
Non-Wilms renal tumors (NWRTs) are a rare group of disorders comprising only 10 to 20% of all pediatric renal tumors. Their timely and accurate identification is critical, as therapeutic approaches differ markedly from those for Wilms tumor. Due to their rarity, the NWRTs remain less well-characterized than Wilms tumor.
Objectives
This study seeks to outline the demographic profile, clinical features, treatment strategies, and survival outcomes of children with NWRTs managed in our center.
Materials and Methods
We conducted a retrospective study on children diagnosed and treated as NWRTs between January 2000 and December 2023 at the pediatric oncology unit of a tertiary care cancer center in Southern India. We categorized the NWRTs into three therapeutic groups: group I: benign tumors requiring surgery only; group II: malignant tumors requiring surgery only; and group III: malignant tumors requiring surgery and chemotherapy—more intensive than the Wilms tumor regimen, with or without radiotherapy
Results
During the study period, 17 children (19% of all renal tumors) were diagnosed with NWRTs in our unit. The distribution of histological variants within our study cohort was as follows: clear cell sarcoma of kidney (n = 6; 35%); renal cell carcinoma (n = 4; 24%), primitive neuroectodermal tumor (n = 2; 12%), non-rhabdomyomatous soft tissue sarcoma (n = 2; 12%), mesoblastic nephroma (n = 2; 12%), and multicystic nephroma (n = 1; 5%). Eleven patients underwent upfront nephrectomy, while six children received preoperative chemotherapy followed by delayed nephrectomy. Pretherapy biopsy was performed in only six patients in our study cohort. The study participants had a median follow-up duration of 97.5 months (range: 25–136 months). The 5-year event-free survival (EFS) and overall survival (OS) rates for the entire study cohort were 59% (95% confidence interval [CI]: 32–78%) and 62% (95% CI: 34–81%), respectively. Group I demonstrated excellent outcomes, with both 5-year EFS and OS rates at 100%. The 5-year EFS and OS rates were both 75% (95% CI: 13–96%) among the participants belonging to group II. The 5-year EFS and OS rates of group III patients were 40% (95% CI: 12–67%) and 43% (95% CI: 12–71%), respectively.
Conclusion
NWRTs represent a rare and diverse group of renal tumors among children. Early and precise diagnosis of NWRTs, coupled with individualized, multidisciplinary treatment strategies, is vital to achieving better outcomes.
Data Availability Statement
The data that support the findings of this study are available with the corresponding author.
Authors' Contributions
V.R. conceived the concept, overlooked entire study process, and validated the data and manuscript. P.S. collected the data, did the formal analysis, and prepared the draft of the manuscript. A.R. verified the data and corrected the manuscript. G.D., B.T.K., and G.V.V. corrected the manuscript. The manuscript has been read and approved by all authors. Each author confirms that the manuscript represents honest and original work.
Patients' Consent
Informed consent was waived off by the Institutional Ethics Committee as this study is a retrospective study using anonymized data.
Publication History
Article published online:
07 November 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Libes J, Hol J, Neto JCA. et al. Pediatric renal tumor epidemiology: global perspectives, progress, and challenges. Pediatr Blood Cancer 2023; 70 (01) e30006
- 2 Nakata K, Colombet M, Stiller CA, Pritchard-Jones K, Steliarova-Foucher E. IICC-3 Contributors. Incidence of childhood renal tumours: an international population-based study. Int J Cancer 2020; 147 (12) 3313-3327
- 3 Graf N, Bergeron C, Brok J. et al. Fifty years of clinical and research studies for childhood renal tumors within the International Society of Pediatric Oncology (SIOP). Ann Oncol 2021; 32 (11) 1327-1331
- 4 Spreafico F, Fernandez CV, Brok J. et al. Wilms tumour. Nat Rev Dis Primers 2021; 7 (01) 75
- 5 Qureshi SS, Bhagat M, Verma K. et al. Incidence, treatment, and outcomes of primary and recurrent non-Wilms renal tumors in children: report of 109 patients treated at a single institution. J Pediatr Urol 2020; 16 (04) 475.e1-475.e9
- 6 Fang YW, Song HC, Sun N, Zhang WP. Non-Wilms' renal tumors in children: experience with 139 cases treated at a single center. BMC Urol 2022; 22 (01) 89
- 7 Garcés-Visier C, Maruszewski P, Luis-Huertas AL. et al. Non-Wilms renal tumors: twenty years experience in a referral center. J Pediatr Surg Open 2024; 8: 100151
- 8 Saula PW, Hadley GP. Pediatric non-Wilms' renal tumors: a third world experience. World J Surg 2012; 36 (03) 565-572
- 9 Zhuge Y, Cheung MC, Yang R, Perez EA, Koniaris LG, Sola JE. Pediatric non-Wilms renal tumors: subtypes, survival, and prognostic indicators. J Surg Res 2010; 163 (02) 257-263
- 10 Ahmed HU, Arya M, Levitt G, Duffy PG, Mushtaq I, Sebire NJ. Part I: primary malignant non-Wilms' renal tumours in children. Lancet Oncol 2007; 8 (08) 730-737
- 11 Ahmed HU, Arya M, Levitt G, Duffy PG, Sebire NJ, Mushtaq I. Part II: treatment of primary malignant non-Wilms' renal tumours in children. Lancet Oncol 2007; 8 (09) 842-848
- 12 Broecker B. Non-Wilms' renal tumors in children. Urol Clin North Am 2000; 27 (03) 463-469 , ix
- 13 Doganis D, Karalexi MA, Panagopoulou P. et al; NARECHEM-ST collaborating group. Incidence patterns of childhood non-Wilms renal tumors: comparing data of the Nationwide Registry of Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST), Greece, and the Surveillance, Epidemiology, and End Results Program (SEER), USA. Cancer Epidemiol 2022; 78: 102153
- 14 Jackson TJ, Brisse HJ, Pritchard-Jones K. et al; SIOP RTSG Biopsy Working Group. How we approach paediatric renal tumour core needle biopsy in the setting of preoperative chemotherapy: a review from the SIOP Renal Tumour Study Group. Pediatr Blood Cancer 2022; 69 (09) e29702
- 15 de la Monneraye Y, Michon J, Pacquement H. et al. Indications and results of diagnostic biopsy in pediatric renal tumors: a retrospective analysis of 317 patients with critical review of SIOP guidelines. Pediatr Blood Cancer 2019; 66 (06) e27641
- 16 Welter N, Metternich G, Furtwängler R. et al. How to improve initial diagnostic accuracy of kidney tumours in childhood?-a non-invasive approach. Int J Cancer 2024; 154 (11) 1955-1966
- 17 Srinivasan S, Ramanathan S, Prasad M. Wilms tumor in India: a systematic review. South Asian J Cancer 2022; 12 (02) 206-212
- 18 Kumar GR, Shah AC, Murali A, Krishnamurthy SS, Radhakrishnan V, Raja A. Surgical practices and oncological outcomes of Wilms tumor in a resource limited setting: a risk-adapted approach. Pediatr Surg Int 2025; 41 (01) 105
- 19 Qureshi SS, Kembhavi SA, Bhagat M. et al. Customized approach for upfront or delayed resection using radiological criteria in unilateral, nonmetastatic pediatric renal tumors: a prospective study. Pediatr Blood Cancer 2019; 66 (Suppl. 03) e27815
- 20 Bhatnagar S. Management of Wilms' tumor: NWTS vs SIOP. J Indian Assoc Pediatr Surg 2009; 14 (01) 6-14
- 21 Geller JI, Cost NG, Chi YY. et al; Children's Oncology Group (COG) Renal Tumor Committee. A prospective study of pediatric and adolescent renal cell carcinoma: a report from the Children's Oncology Group AREN0321 study. Cancer 2020; 126 (23) 5156-5164
- 22 van der Beek JN, Hol JA, Coulomb-l'Hermine A. et al. Characteristics and outcome of pediatric renal cell carcinoma patients registered in the International Society of Pediatric Oncology (SIOP) 93-01, 2001 and UK-IMPORT database: a report of the SIOP-Renal Tumor Study Group. Int J Cancer 2021; 148 (11) 2724-2735
- 23 Aldrink JH, Heaton TE, Dasgupta R. et al; American Pediatric Surgical Association Cancer Committee. Update on Wilms tumor. J Pediatr Surg 2019; 54 (03) 390-397
- 24 Vujanić GM, Gessler M, Ooms AHAG. et al; International Society of Paediatric Oncology–Renal Tumour Study Group (SIOP–RTSG). The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nat Rev Urol 2018; 15 (11) 693-701
